Back to search

Article

A Glutamine antagonist-modulated tumor microenvironment unleashes enzalutamide’s immunotherapeutic effects

2026-07-01

Abstract excerpt

Androgen receptor (AR) antagonists, such as enzalutamide, suppress prostate cancer (PCa) cells to achieve temporary therapeutic effects. In addition to tumor cell-autonomous suppressive function, AR antagonists can also potentially exert anti-tumor effects via mitigating cytotoxic T cells’ exhaustion. However, strategies for effectively harnessing enzalutamide’s immunotherapeutic effects remain elusive. In studyin...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d1debf51-a7e2-5d93-bbcd-011bcb5b5b0f
DOI
10.64898/2026.06.30.735585
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A Glutamine antagonist-modulated tumor microenvironment unleashes enzalutamide’s immunotherapeutic effectsDOI 10.64898/2026.06.30.735585
Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).Semantic proximity
Inhibition of Galectin-1 and androgen receptor axis enhances enzalutamide treatment in enzalutamide resistant prostate cancerSemantic proximity
GRIN3A defines an immunosuppressive niche in advanced prostate cancerSemantic proximity
Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived XenograftsSemantic proximity
Fc-enhanced anti-CTLA-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancerSemantic proximity
Inhibition of Glutamine Metabolism Suppresses Tumor Progression through Remodeling of the Macrophage Immune MicroenvironmentSemantic proximity
Deciphering the suppressive immune microenvironment of prostate cancer based on CD4+ regulatory T cells: Implications for prognosis and therapy predictionSemantic proximity
Targeting the TLK1-Nek1-Mediated Activation of YAP1 Attenuates PD-L1 and Inflammation Set for Prostate Cancer ImmunoevasionSemantic proximity
CCR4 blockade leads to clinical activity and prolongs survival in a canine model of advanced prostate cancerSemantic proximity
ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.Semantic proximity
Regulatory T cell targeting in cancer: Emerging strategies in immunotherapySemantic proximity
High-Dose-Androgen-Induced Autophagic Cell Death to Suppress the Enzalutamide-Resistant Prostate Cancer Growth Via Altering the circRNA-BCL2/miRNA-198/AMBRA1 SignalingSemantic proximity
Select a neighboring publication to make it the new centre.